{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:28:44Z","timestamp":1648974524879},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1994,3,1]],"date-time":"1994-03-01T00:00:00Z","timestamp":762480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[1994,3]]},"DOI":"10.1007\/bf01202198","type":"journal-article","created":{"date-parts":[[2005,2,18]],"date-time":"2005-02-18T15:54:16Z","timestamp":1108742056000},"page":"173-178","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer"],"prefix":"10.1007","volume":"120","author":[{"given":"A.","family":"du Bois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. G.","family":"Meerpohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Madjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bauknecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/bmj.303.6807.884","volume":"303","author":"Advanced Ovarian Cancer Trialist Group","year":"1991","unstructured":"Advanced Ovarian Cancer Trialist Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized trials. Br Med J 303:884?893","journal-title":"Br Med J"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1471-0528.1981.tb01196.x","volume":"88","author":"GH Barker","year":"1981","unstructured":"Barker GH, Wiltshaw E (1981) Use of high dosecis-dichlorodiammine platinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynecol 88:1192?1199","journal-title":"Br J Obstet Gynecol"},{"key":"CR3","first-page":"A1060","volume":"31","author":"RS Benjamin","year":"1990","unstructured":"Benjamin RS, Fenoglio C, Hortobagyi GN et al. (1990) Cardiotoxicity of pirarubicin. Proc Annu Meet Am Assoc Cancer Res 31:A1060","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0277-5379(89)90113-2","volume":"25","author":"P Berthaud","year":"1989","unstructured":"Berthaud P, Le Chevalier T, Berille J et al. (1989) Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer 25:1507?1508","journal-title":"Eur J Cancer"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","volume":"28","author":"A Bois du","year":"1992","unstructured":"Bois A du, Meerpohl HG, Vach W, Kommoss FGM, Fenzl E, Pfleiderer A (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 28:450?457","journal-title":"Eur J Cancer"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000417974","volume":"37","author":"K Bremer","year":"1989","unstructured":"Bremer K, Rieche K, Essers U, Quei\ufffder U (1989) Pirarubicin in advanced low-grade malignant non-Hodgkin's lymphomas. Contrib Oncol 37:119?124","journal-title":"Contrib Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.1989.234","volume":"60","author":"MH Bronchud","year":"1989","unstructured":"Bronchud MH, Howell A, Crowther D, Hopwood P, Souza I, Dexter TM (1989) The use of granulocyte conoly-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121?125","journal-title":"Br J Cancer"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0090-8258(81)90095-0","volume":"12","author":"HW Bruckner","year":"1981","unstructured":"Bruckner HW, Wallach R, Cohen CJ et al. (1981) High dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 12:64?67","journal-title":"Gynecol Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/0277-5379(90)90173-Q","volume":"26","author":"R Coleman","year":"1990","unstructured":"Coleman R, Towlson E, Wiltshaw E et al (1990) Epirubicin for pretreated advanced ovarian cancer. Eur J Cancer 26:850?851","journal-title":"Eur J Cancer"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000417972","volume":"37","author":"P Drings","year":"1989","unstructured":"Drings P, Tessen HW, Gatzemeier U et al. (1989) Phase II study of pirarubicin (THP-doxorubicin) in advanced non-small cell lung cancer. Contrib Oncol 37:103?113","journal-title":"Contrib Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000226835","volume":"47","author":"S Eckhardt","year":"1990","unstructured":"Eckhardt S, Hermadi Z, Thurzo L et al. (1990) Phase II clinical evaluation od etoposide as a second-line treatment in ovarian cancer. Oncology 47:289?295","journal-title":"Oncology"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","volume":"36","author":"ME Gore","year":"1990","unstructured":"Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207?211","journal-title":"Gynecol Oncol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-108-2-165","volume":"108","author":"JD Hainsworth","year":"1988","unstructured":"Hainsworth JD, Grosh WW, Burrett LS et al. (1988) Advanced ovarian cancer: long term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 108:165?170","journal-title":"Ann Intern Med"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00171980","volume":"8","author":"A Harstrick","year":"1990","unstructured":"Harstrick A, Casper J, Koehne-Woemper H, Wilke H, Schmoll HJ, Poliwoda H (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. Invest New Drugs 8:19?24","journal-title":"Invest New Drugs"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000417973","volume":"37","author":"A Henss","year":"1989","unstructured":"Henss A, Arnold H, Fiebig HH, Loehr GW (1989) Phase II study of pirarubicin in small cell lung carcinoma. Contrib Oncol 37:114?118","journal-title":"Contrib Oncol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/0959-8049(92)90066-B","volume":"28A","author":"P Herait","year":"1992","unstructured":"Herait P, Poutignat N, Marty M, Bugat R (1992) Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 28A:1670?1676","journal-title":"Eur J Cancer"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00177409","volume":"1","author":"K Inoue","year":"1983","unstructured":"Inoue K, Arakowa M, Miyamoto H, Ogawa M (1983) Activity of 4?-O-tetrahydropyranyl-Adriamycin hydrochloride (THP-Adriamycin) in a human tumor cloning system. Invest New Drugs 1:271?275","journal-title":"Invest New Drugs"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-2007-998159","volume":"69","author":"H Iro","year":"1990","unstructured":"Iro H, Koenig HJ (1990) Phase II Studie mit Pirarubicin bei vorbehandeltem progredienten Kopf-Hals-Malignomen. Laryngorhinootologie 69:131?134","journal-title":"Laryngorhinootologie"},{"key":"CR19","first-page":"175","volume":"13","author":"UR Kleeberg","year":"1990","unstructured":"Kleeberg UR, Reichel L, Wander HE et al. (1990) Phase II study of pirarubicin in metastatic breast cancer. Onkologie 13:175?179","journal-title":"Onkologie"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.1990.8.4.705","volume":"8","author":"F Levi","year":"1990","unstructured":"Levi F, Benavides M, Chevelle C et al. (1990) Chemotherapy of advanced ovarian cancer with 4?-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensisty. J Clin Oncol 8:705?714","journal-title":"J Clin Oncol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.1986.4.11.1579","volume":"4","author":"KG Louie","year":"1986","unstructured":"Louie KG, Ozols RF, Myers LE et al. (1986) Long term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 4:1579?1585","journal-title":"J Clin Oncol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Hoskins W (1992) Response to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population (Editorial). J Clin Oncol 10:513?514","journal-title":"J Clin Oncol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389?393","journal-title":"J Clin Oncol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","volume":"111","author":"WP McGuire","year":"1989","unstructured":"McGuire WP, Rowinsky EK, Rosensheim NB et al. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med 111:273?279","journal-title":"Ann Intern Med"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0014-2964(81)90005-0","volume":"17","author":"J Menczer","year":"1981","unstructured":"Menczer J, Baitner S, Modan M, Chaitchik S, Brenner H (1981) Response to second line chemotherapy in ovarian cancer of epithelial origin. Eur J Cancer Clin Oncol 17:1259?1262","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR26","first-page":"196","volume":"11","author":"GH Mickisch","year":"1992","unstructured":"Mickisch GH, Gottesman MM, Pastan L (1992) New chemosensitizers to reverse multidrug resistance in renal cell carcinoma and in mdrtransgenic mice (abstract 597). Proc ASCO 11:196","journal-title":"Proc ASCO"},{"key":"CR27","first-page":"1461","volume":"47","author":"AA Miller","year":"1987","unstructured":"Miller AA, Schmidt CG (1987) Clinical pharmacology and toxicity of 4?-O-tetrahydropyranyladriamycin. Cancer Res 47:1461?1465","journal-title":"Cancer Res"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47:207?214","journal-title":"Cancer"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.annonc.a058056","volume":"3","author":"JP Neijt","year":"1992","unstructured":"Neijt JP (1992) Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 3:17?27","journal-title":"Ann Oncol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1991.9.9.1668","volume":"9","author":"Ovarian Cancer Meta-analysis Project","year":"1991","unstructured":"Ovarian Cancer Meta-analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9:1668?1674","journal-title":"J Clin Oncol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.1987.5.2.197","volume":"5","author":"RF Ozols","year":"1987","unstructured":"Ozols RF, Ostchega Y, Curt G, Young RC (1987) High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5:197?201","journal-title":"J Clin Oncol"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00258458","volume":"23","author":"C Redman","year":"1989","unstructured":"Redman C, Lawton F, Stuart N et al. (1989) Phase II study of combination 4?-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 23:51?53","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR33","first-page":"1060","volume":"13","author":"T Saito","year":"1986","unstructured":"Saito T, Kasai Y, Wakin A et al. (1986) Phase II study of (2?R-(4?-O-tetrahydropyranyl-Adriamycin (THP) in patients with solid tumors. Jpn J Cancer Chemother 13:1060?1069","journal-title":"Jpn J Cancer Chemother"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00177262","volume":"8","author":"W Scheithauer","year":"1990","unstructured":"Scheithauer W, Samonigg H, Depisch D et al. (1990) Pirarubicin for treatment of advanced breast cancer. Invest New Drugs 8:207?210","journal-title":"Invest New Drugs"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000417968","volume":"37","author":"M Schroeder","year":"1989","unstructured":"Schroeder M, Donhuijsen-Ant R, Purea H, Westerhausen M (1989) Clinical experience with pirarubicin in the treatment of patients with pretreated head and neck cancer. Contrib Oncol 37:74?77","journal-title":"Contrib Oncol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0277-5379(90)90161-L","volume":"26","author":"M Spielmann","year":"1990","unstructured":"Spielmann M, Kerbat P, Delozier T et al. (1990) Pirarubicin in advanced breast cancer: French cooperative phase II study. Eur J Cancer 26:821?823","journal-title":"Eur J Cancer"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/1097-0142(19890315)63:6<1084::AID-CNCR2820630608>3.0.CO;2-U","volume":"63","author":"KS Sridhar","year":"1989","unstructured":"Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of pirarubicin in malignant mesothelioma. Cancer 63:1084?1091","journal-title":"Cancer"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/1097-0142(19901115)66:10<2082::AID-CNCR2820661007>3.0.CO;2-5","volume":"66","author":"KS Sridhar","year":"1990","unstructured":"Sridhar KS, Samy SA, Agarwal RP et al. (1990) A phase II study of 4?-O-tetrahydropyranyladriamycin. Cancer 66:2082?2091","journal-title":"Cancer"},{"key":"CR39","first-page":"A156","volume":"9","author":"T Thigpen","year":"1990","unstructured":"Thigpen T, Blessing J, Ball H et al. (1990) Phase II trial of taxol as second-line therapy for ovarian carcinoma: Gynecologic Oncology Group study. Proc Am Assoc Clin Oncol 9:A156","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0753-3322(89)90008-5","volume":"43","author":"T Tominaga","year":"1989","unstructured":"Tominaga T, Abe O, Enomoto K et al. (1989) A randomized controlled study of (2?R)-4?-O-tetrahydropyranyladriamycin and Adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Biomed Pharmacother 43:271?278","journal-title":"Biomed Pharmacother"},{"key":"CR41","doi-asserted-by":"crossref","unstructured":"Untch M, Sevin BU, Perras J et al. (1992) Evaluation of chemosensitivity to pirarubicin and other chemotherapeutic agents in primary and recurrent gynecologic malignancies. Gynecol Oncol (in press)","DOI":"10.1016\/0090-8258(92)90102-O"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0277-5379(91)90507-A","volume":"27","author":"MEL Burg Van der","year":"1991","unstructured":"Van der Burg MEL, Hoff AM, Lent M van, Rodenburg CJ, Putten WLJ van, Stoter G (1991) Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 27:248?250","journal-title":"Eur J Cancer"},{"key":"CR43","first-page":"A1117","volume":"31","author":"JB Vermorken","year":"1990","unstructured":"Vermorken JB, Bokkel Huinnik WW ten, Kobierska A et al. (1990) Antitumor activity of high dose epirubicin in patients with ovarian cancer failing platinum-based regimens. Proc Am Assoc Cancer Res Annu Meet 31:A1117","journal-title":"Proc Am Assoc Cancer Res Annu Meet"},{"issue":"Suppl 1","key":"CR44","first-page":"A328","volume":"3","author":"JB Vermorken","year":"1992","unstructured":"Vermorken JB, Kobierska A, Zanaboni F et al. (1992) Phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. Ann Oncol 3 [Suppl 1]:A328","journal-title":"Ann Oncol"},{"key":"CR45","unstructured":"WHO (1979) Handbook for reporting the results of cancer treatment. WHO Offset Publ 48"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000417969","volume":"37","author":"P Worst","year":"1989","unstructured":"Worst P, Fiebig HH, Harstrick A, Donhuijsen-Ant R, Edler L, Quei\ufffder W (1989) Pirarubicin in advanced soft tissue sarcomas. Contrib Oncol 37:78?88","journal-title":"Contrib Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01202198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01202198\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01202198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T21:14:42Z","timestamp":1586121282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01202198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,3]]}},"alternative-id":["BF01202198"],"URL":"https:\/\/doi.org\/10.1007\/bf01202198","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,3]]}}}